The AXIS Study: the Efficacy of Acetazolamide for the Treatment of Cystoid Fluid Collections in Retinoschisis
NCT06114537
Eye Diseases, Retinal Degeneration
Amsterdam, North Holland, Netherlands
View Trial DetailsNCT Number: NCT00055029
This study will explore the causes and eye problems of X-linked juvenile retinoschisis (XLRS), an inherited disease that causes vision loss primarily in young males. The vision loss, which worsens over time, is a result of schisis, or splitting, of the layers of the retina (tissue that lines the back of the eye). A better understanding of why and how XLRS develops might lead to improved treatments.
Patients 9 months of age and older with XLRS and females who are suspected carriers of the gene responsible for the disease (such as the mother of the patient) may be eligible for this study. Other family members of patients also may be enrolled.
Patients will undergo the following tests and procedures:
* Personal and family medical history to review past and current medical conditions and treatments, particularly regarding eye disease, and to construct a family tree. * Eye examination to assess visual acuity (eye chart test) and examine pupils, lens, retina, and eye movements. The pupils will be dilated with drops for this examination. * Photography of the retina to help evaluate the status of the retina. * Specialized eye tests to evaluate color vision, field of vision, and ability to see in the dark. * Electroretinogram (ERG) to examine what happens to the eyes after a flash of bright light. For this test, the patient sits in a dark room for 30 minutes with his or her eyes patched. Then, a small silver disk electrode is taped to the forehead, the eye patches are removed, the surface of the eye is numbed with eye drops and contact lenses are placed on the eyes. The patient looks inside a large empty bowl and then a light flashes, first in the dark and then with a light turned on inside the bowl. The contact lenses sense small electrical signals generated by the retina when the light flashes. * Blood test to examine DNA for genetic study of XLRS.
Family members will provide a blood sample for genetic study.
Looking for future studies?
Notify Me9 month–100 year
All sexes
Observational
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Objectives:
The overall goal of this protocol is to better understand the etiology of XLRS disease to facilitate further research to identify a potential treatment for the disease. The specific primary objectives of this study are to:
correlation.
With the opportunity to study the genotypes and phenotypes of many affected males and the genotype of family members, a secondary objective of this study will be to develop a detailed pedigree for affected families. This information may be used to develop preliminary risk estimates for potential carrier females.
Study Population:
Up to 500 participants may enroll in this study. A minimum of 150 of participants are expected to be males diagnosed with X-Linked Retinoschisis. Participants may be recruited from the NIH and also from participating off-site locations. The quality of the genetic observation is directly proportional to the number of affected individuals and genetically-different families enrolled.
Design:
This natural history, multi-center, registry study to enroll males diagnosed with X-Linked Retinoschisis and the family members of affected individuals. Onsite affected males will undergo clinical examination and have their blood drawn for genotyping. Onsite unaffected participants will undergo eye examinations. Blood may also be drawn from the onsite unaffected participants but this is not required. Sites outside of NIH are participating as referral centers to accumulate the cohort. Offsite affected male participants will forward a blood sample and records from previous eye examinations to the NEI for review and analysis. Offsite unaffected participants will forward records from previous eye examinations and may provide a blood sample although this is not required.
Outcome Measures:
The primary outcome is the categorization of the proband s genotype and phenotype and determination of the relationship between the two.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Eligible participants must satisfy one of the criteria below:
The participant (or the participant s legal guardian) understands and signs this protocol s informed consent document and minor participants between the ages of 7 and 17 must provide assent.
Exclusion criteria
Affected males will be ineligible for participation if:
Both affected and unaffected individuals will be ineligible for participation if:
Time frame: ongoing
The overall goal of this protocol is to better understand the etiology of XLRS disease to facilitate further research to identify a potential treatment for the disease.
Time frame: ongoing
The overall goal of this protocol is to better understand the etiology of XLRS disease to facilitate further research to identify a potential treatment for the disease.
Time frame: ongoing
This information may be used to develop preliminary risk estimates for potential carrier females
National Eye Institute (NEI)
Nih
X-Linked Juvenile Retinoschisis - Clinical and Molecular Studies
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06114537
Eye Diseases, Retinal Degeneration
Amsterdam, North Holland, Netherlands
View Trial DetailsNCT02317887
Eye Diseases, Retinal Degeneration
Bethesda, Maryland, United States
View Trial DetailsNCT02317354
Eye Diseases, Retinal Degeneration
Bethesda, Maryland, United States
View Trial DetailsNCT03354403
Eye Diseases, Retinal Degeneration
Bethesda, Maryland, United States
View Trial Details